FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987138081> ?p ?o ?g. }

• W1987138081 endingPage "F110" @default.
• W1987138081 startingPage "F103" @default.
• W1987138081 abstract "To investigate the steady-state pharmacokinetics of a once-daily dosing regimen of saquinavir soft gelatin capsules in combination with a low dose of ritonavir in HIV-1-infected individuals.Open-label, multi-dose, pharmacokinetic pilot study.Seven HIV-1-infected individuals who were treated with saquinavir hard gelatin capsules 400 mg twice daily + ritonavir liquid formulation 400 mg twice daily were switched to saquinavir soft gelatin formulation 1600 mg once daily in combination with ritonavir liquid formulation 200 mg once daily (day 0). Patients were instructed to ingest saquinavir and ritonavir simultaneously in the morning and with a meal.Steady-state pharmacokinetics of saquinavir and ritonavir were assessed during a 24 h dosing interval after 2 weeks of continued therapy (day 14). Plasma saquinavir and ritonavir concentrations were measured using a validated high performance liquid chromatography assay. In addition, plasma HIV-1 RNA, and fasting total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglyceride levels were measured on days 0 and 14. A non-compartmental pharmacokinetic method was used to calculate the area under the plasma concentration versus time curve (AUC[0-24h]), the maximum and trough plasma concentrations (Cmax and Cmin), the time to reach Cmax (Tmax), the elimination half-life (t1/2), the apparent clearance (Cl/F), and the apparent volume of distribution (V/F).Median (range) values of the pharmacokinetic parameters for saquinavir after 2 weeks of treatment were: AUC[0-24h], 19,802h* ng/ml (3720-74,016); Cmax, 2936 ng/ml (573-6848); Cmin, 84 ng/ml (11-854); Tmax, 3.5 h (3.0-4.0), t1/2, 6.8 h (4.6-10.2); Cl/F, 81 l/h (22-430); V/F, 1189 l (215-3086). Ritonavir concentrations were always below the 90% effective concentration of 2100 ng/ml (median Cmax, 1323 ng/ml; range, 692-1528 ng/ml). No significant changes were observed for total serum cholesterol, high-density lipoprotein, and low-density lipoprotein levels between days 0 and 14 (P > or = 0.24). In six out of seven patients the fasting serum triglyceride levels were lower 2 weeks after the treatment switch (median decrease was 32%, P = 0.03). No significant changes in plasma HIV-1 RNA concentrations were observed between days 0 and 14. The regimen was generally well tolerated.This pharmacokinetic study indicates that the combination of 1600 mg of saquinavir (soft gelatin capsules) and 200 mg of ritonavir (liquid formulation) in a once-daily dosing regimen generally results in therapeutic plasma concentrations of saquinavir. Due to the large interindividual variation in saquinavir exposure, the monitoring of saquinavir concentrations in plasma is warranted. These pharmacokinetic findings rationalize the further clinical evaluation of once-daily dosing of this combination of protease inhibitors." @default.
• W1987138081 created "2016-06-24" @default.
• W1987138081 creator A5009130655 @default.
• W1987138081 creator A5018761768 @default.
• W1987138081 creator A5027819349 @default.
• W1987138081 creator A5030426323 @default.
• W1987138081 creator A5062227574 @default.
• W1987138081 creator A5062571600 @default.
• W1987138081 creator A5071774997 @default.
• W1987138081 date "2000-06-01" @default.
• W1987138081 modified "2023-10-18" @default.
• W1987138081 title "Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study" @default.
• W1987138081 cites W1558522890 @default.
• W1987138081 cites W1578036306 @default.
• W1987138081 cites W1589151529 @default.
• W1987138081 cites W1977509185 @default.
• W1987138081 cites W2006069153 @default.
• W1987138081 cites W2014842368 @default.
• W1987138081 cites W2042312816 @default.
• W1987138081 cites W2069947800 @default.
• W1987138081 cites W2087182797 @default.
• W1987138081 cites W2108524243 @default.
• W1987138081 cites W2121690400 @default.
• W1987138081 cites W2150716583 @default.
• W1987138081 cites W2155706932 @default.
• W1987138081 cites W2171550471 @default.
• W1987138081 cites W2314026148 @default.
• W1987138081 cites W2318289184 @default.
• W1987138081 cites W2323801285 @default.
• W1987138081 cites W2324224482 @default.
• W1987138081 cites W4251307042 @default.
• W1987138081 doi "https://doi.org/10.1097/00002030-200006160-00003" @default.
• W1987138081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10894270" @default.
• W1987138081 hasPublicationYear "2000" @default.
• W1987138081 type Work @default.
• W1987138081 sameAs 1987138081 @default.
• W1987138081 citedByCount "41" @default.
• W1987138081 countsByYear W19871380812013 @default.
• W1987138081 countsByYear W19871380812014 @default.
• W1987138081 countsByYear W19871380812016 @default.
• W1987138081 countsByYear W19871380812021 @default.
• W1987138081 countsByYear W19871380812023 @default.
• W1987138081 crossrefType "journal-article" @default.
• W1987138081 hasAuthorship W1987138081A5009130655 @default.
• W1987138081 hasAuthorship W1987138081A5018761768 @default.
• W1987138081 hasAuthorship W1987138081A5027819349 @default.
• W1987138081 hasAuthorship W1987138081A5030426323 @default.
• W1987138081 hasAuthorship W1987138081A5062227574 @default.
• W1987138081 hasAuthorship W1987138081A5062571600 @default.
• W1987138081 hasAuthorship W1987138081A5071774997 @default.
• W1987138081 hasBestOaLocation W19871380811 @default.
• W1987138081 hasConcept C112705442 @default.
• W1987138081 hasConcept C139254425 @default.
• W1987138081 hasConcept C142462285 @default.
• W1987138081 hasConcept C159047783 @default.
• W1987138081 hasConcept C185592680 @default.
• W1987138081 hasConcept C22979827 @default.
• W1987138081 hasConcept C2776937687 @default.
• W1987138081 hasConcept C2777288759 @default.
• W1987138081 hasConcept C2778335254 @default.
• W1987138081 hasConcept C2779298103 @default.
• W1987138081 hasConcept C2910800852 @default.
• W1987138081 hasConcept C2993143319 @default.
• W1987138081 hasConcept C3013748606 @default.
• W1987138081 hasConcept C71924100 @default.
• W1987138081 hasConcept C98274493 @default.
• W1987138081 hasConceptScore W1987138081C112705442 @default.
• W1987138081 hasConceptScore W1987138081C139254425 @default.
• W1987138081 hasConceptScore W1987138081C142462285 @default.
• W1987138081 hasConceptScore W1987138081C159047783 @default.
• W1987138081 hasConceptScore W1987138081C185592680 @default.
• W1987138081 hasConceptScore W1987138081C22979827 @default.
• W1987138081 hasConceptScore W1987138081C2776937687 @default.
• W1987138081 hasConceptScore W1987138081C2777288759 @default.
• W1987138081 hasConceptScore W1987138081C2778335254 @default.
• W1987138081 hasConceptScore W1987138081C2779298103 @default.
• W1987138081 hasConceptScore W1987138081C2910800852 @default.
• W1987138081 hasConceptScore W1987138081C2993143319 @default.
• W1987138081 hasConceptScore W1987138081C3013748606 @default.
• W1987138081 hasConceptScore W1987138081C71924100 @default.
• W1987138081 hasConceptScore W1987138081C98274493 @default.
• W1987138081 hasIssue "9" @default.
• W1987138081 hasLocation W19871380811 @default.
• W1987138081 hasLocation W19871380812 @default.
• W1987138081 hasLocation W19871380813 @default.
• W1987138081 hasOpenAccess W1987138081 @default.
• W1987138081 hasPrimaryLocation W19871380811 @default.
• W1987138081 hasRelatedWork W1987138081 @default.
• W1987138081 hasRelatedWork W2013703413 @default.
• W1987138081 hasRelatedWork W2039093847 @default.
• W1987138081 hasRelatedWork W2054172655 @default.
• W1987138081 hasRelatedWork W2077031675 @default.
• W1987138081 hasRelatedWork W2151288869 @default.
• W1987138081 hasRelatedWork W2162817959 @default.
• W1987138081 hasRelatedWork W2376087219 @default.
• W1987138081 hasRelatedWork W2409947583 @default.
• W1987138081 hasRelatedWork W4226029827 @default.
• W1987138081 hasVolume "14" @default.

• next